Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

ATP5B (ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide)

Written2014-11Esra Bozgeyik, Kaifee Arman, Yusuf Ziya Igci
University of Gaziantep, Faculty of Medicine, Department of Medical Biology, Gaziantep, Turkey

Abstract Review on ATP5B, with data on DNA/RNA, on the protein encoded and where the gene is implicated.

(Note : for Links provided by Atlas : click)

Identity

Alias_namesATPSB
Other aliasATPMB
HEL-S-271
HGNC (Hugo) ATP5B
LocusID (NCBI) 506
Atlas_Id 51209
Location 12q13.3  [Link to chromosome band 12q13]
Location_base_pair Starts at 56638175 and ends at 56646068 bp from pter ( according to hg19-Feb_2009)  [Mapping ATP5B.png]
Fusion genes
(updated 2016)
ATP5B (12q13.3) / ATP5B (12q13.3)ATP5B (12q13.3) / CLU (8p21.1)ATP5B (12q13.3) / MSI2 (17q22)
ATP5B (12q13.3) / PTGES3 (12q13.3)ATP5B (12q13.3) / PTMA (2q37.1)FMN1 (15q13.3) / ATP5B (12q13.3)
HADH (4q25) / ATP5B (12q13.3)RBMS2 (12q13.3) / ATP5B (12q13.3)UBE2T (1q32.1) / ATP5B (12q13.3)

DNA/RNA

 
  Figure 1. A. Location of ATP5B gene and the representation of its transcript. ATP5B gene is localized on 12q13.13 on minus strand and contains exonic regions. B. Location of ATP5BP1 (ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypepide pseudogene 1) and pseudogene.
Description The human ATP5B gene is located on the minus strand and spans 7894 bps of genomic region (56638175 - 56646068). ATP5B gene sequence shows partial homology with chromosomes 2 and 17. There are 13 Alu repeat sequences. Among these sequences, 4 were found to be inside the intron and the rest were towards the upstream side. ATP5B gene consists of four "CCAAT" sequences upstream and these sequences are much closer to the transcriptional initiation site (Neckelmann et al., 1989). This gene encodes a single transcript as presented in NCBI database. It has 10 exons and mRNA size 1857 bp. It has 529 amino acids (aa) and its size is about 56 kDa (figure 1A).
Transcription ATP5B gene transcript is assigned in the reference database as well as ensemble data base including 11 splice variants which are described as ENST00000262030, ENST00000552959, ENST00000551020, ENST00000553007, ENST00000551570, ENST00000550162, ENST00000547250, ENST00000547808, ENST00000548647, ENST00000551182, ENST00000548474. The level of mRNA transcript reveals marked differences between tissues. It is mostly expressed in the heart while it is less expressed in the skeletal muscles. It is also less expressed in liver and kidney. These findings suggest that tissue-specific mRNA levels of ATP5B can occur with transcriptional control (Neckelmann et al., 1989). The exact function of ATP5B is not known and the level of ATP5B gene expression has been shown to fall in different human tumors as compared to normal tissues (Willers et al., 2010). ATP5B transcripts were found to be highly expressed in colorectal cancer patients (Geyik et al., 2014).
Pseudogene A pseudogene named ATP5BP1 has been found on chromosome number 2 with contig number NC_000002.12 (reference GRCh38 Primary Assembly) for ATP5B gene. This pseudogene is encoded in the intronic region of the VWA3B gene. It is localized on 2q11.2 and is also known by other terms like ATP5BL1; ATPMBL1; ATPSBL. It is 1783 nt in length (figure 1B).

Protein

 
  Figure 2. ATP5B protein sequence data showing beta-barrel domain (brown colored), nucleotide binding domain (blue colored), C terminal domain (green colored), Walker A motif (light pink), Walker B motif (orange colored), polypeptide binding site (black), ATP binding site (chemical binding) (red colored), inhibitor binding site (dark pink).
Description ATP synthase beta subunit which is ATP5B protein and is also known as mitochondrial precursor is encoded by ATP5B gene. During oxidative phosphorylation, it maintains the electrochemical tendency of the protons in the membrane as well as it possess 5 sub units of ATP synthase enzyme like alpha (α), beta (β), gamma (γ), delta (Δ) and epsilon (ε) which acts as a catalyst in ATP synthesis. ATP5B constitutes the beta-subunit of ATP synthase enzyme and this enzyme is formed of 529 amino acid residues. Figure 2 shows that the molecular weight of this protein is 56559.90 g/mol and isoelectric point is 5.0668. The amino acid sequence of this protein and domain are also shown.
ATP5B protein is composed of three domains: ATP synthase alpha/beta family, beta-barrel domain (63-129 aa), F1 ATP synthase beta subunit nucleotide binding domain (131-420 aa), ATP synthase alpha/beta chain C-terminal domain (418-525 aa). It consists of a large family of proteins consisting of ATP-binding cassette transporter nucleotide-binding domains; ABC transporters, ions, sugar and different components transporting peptides and organic molecules. This nucleotide binding domain resembles to all other members of this family protein. It consists of ABC transporter, the Q-loop, and H-loop/switch region and in addition consists of a subset of nucleotide hydralazine motifs such as Walker A motif/P-loop and Walker B motifs that are mainly found in many hydrolysis proteins and several ATP and GTP-binding proteins.
Expression In oxidative phosphorylation, the cellular relative expression level of ATP5B protein was compared between normal and tumor tissues. It has been reported that there was less expression in tumor tissues as compared to normal (Cuezva et al., 2004). ATP5B gets down regulated in some cancers and helps to increase the expression of some glycolytic pathway markers. The cell death response with chemical agents shows correlation with oxidative phosphorylation as well as ATP5B expression (Cuezva et al., 2009; Lin et al., 2008; Shin et al., 2005). ATP5B expression was found to be significantly lower in esophageal and breast cancer cells as compared to normal tissues (Acebo et al., 2009). ATP5B protein expression in the cancer tissue was found to be down-regulated as compared to normal tissues (Cuezva et al., 2002; López-Ríos et al., 2007; Willers et al., 2010). The mitochondrial localization and translation of β-F1-ATPase mRNA (termed β-mRNA) are known to be primary sites for regulating the spatial and temporal expression of the protein as it is indicated by the expression of β-F1-ATPase in the liver, in brown adipose tissue and during cell cycle progression.
Localisation The ATP5B protein is localized to the mitochondrion inner membrane.
Function As many other proteins, ATP5B has ATP and protein binding functions. The majority of cellular energy is synthesized in the form of ATP by ATP synthase. The force for ATP synthesis eventually comes from Na+ gradient which further activates an electrochemical proton rotation which takes place around F0 motor particles in the membrane. The effective rotation does not only require DeltamuH(+), membrane containing the potentials (Deltapsi) and proton concentration gradient (DeltapH) but also requires high proton concentration from the P sources (Von Ballmoos et al., 2009).
The enzyme catalyzed oxidation of metabolic substances like glucose, fatty acids and amino acids are transferred to electron carriers. These electrons are then transferred to the electron transport system (ETS) located in the mitochondrial membrane. ATP synthase enzyme gets activated with the resulting proton gradient. ATP synthesis takes place by F0-F1 ATP synthase enzyme complex as a result of power produced by protons in the matrix. ATP5B protein also plays an important role in the oxidative phosphorylation during the formation of beta subunit of F1 unit of ATP synthase enzyme.
In an study conducted with human immunodeficiency virus (HIV)-1, replication was found to be inhibited in HeLa P4 / R5 cells after the siRNA mediated knockdown of ATP5B (Zhou et al., 2008). ATP5B was shown to be upregulated by Tat protein of HIV-1 virus (López-Huertas et al., 2013). ATP5B protein was also shown to be physically interacted with Vpr, a HIV-1 virus protein in HEK293 cells (Barrero et al., 2013).
Metabolic changes are common characteristic features of cancer tissues. The downregulation of oxidative phosphorylation is a distinguishing feature of many cancer types. The decrease in expression of subunit of F1 unit of ATP synthase enzyme has been associated with many malignant cancers (Xiao et al., 2013).
Angiostatin which is an angiogenesis inhibitor binds to ATP synthase found on endothelial cell surface and inhibits it. It also regulates cellular pH in cell acidosis and impairs endothelial cell formation. The agonist of ATP synthase MAb3D5AB1, recognizes catalytic β-subunit of ATP synthase and inhibits the activity of F1 domain (Chi et al., 2007). Mab3d5ab1 shows angiostatin-like properties and can be useful in the chemotherapy (Chi et al., 2007).
Homology ATP5B gene sequence shows homology to chromosomes 2 of 17 (Neckelmann et al., 1989). It also shows homology to other organisms in following manner. It shows homology to P. troglodytes 99%, M.mullata 98%, C. lupus 92%, M. musculus 89%, R. norvegicus 89%, G. gallus 78%, D. melanogaster 74%, C. elegans, 70%, S. cerevisiae 69% (data from NCBI BLAST).

Mutations

Note There has been no mutation identified in ATP5B till now. However, many variations have been identified on these genes: approximately 190 single nucleotide variant, 35 missense variant, 20 synonyms variant, 110 intron variant, 11 deletion, 8 insertion, 1 indel, 1 splice donor variant, 3 5'UTR variant, 6 3' UTR variant.

Implicated in

Note
  
Entity Colorectal cancer
Prognosis Many studies show low expression of mitochondrial ATP synthase in many cancers including lung cancer, breast cancer and colorectal cancer (Willers et al., 2010). In addition, shorter life span of colorectal cancer patients has been associated with the low expression of ATP5B gene. In a study on colorectal cancer patients, ATP5B expression was found to be increased in tumor tissues as compared to normal ones and a significant increase in ATP5B gene expression was found in patients under 45 years of age (Geyik et al., 2014).
  
  
Entity Breast cancer
Prognosis Breast cancer is a common malignancy in women worldwide. ATP5B was found to be upregulated in breast cancer tissues in a significant manner. This protein can even play an important role as a target protein in the treatment of cancers. Using ATP synthase inhibitor aurovertin B, in breast cancer cells MCF-7, the effect of ATP5B protein in tumor progression was found to be reduced (Huang et al., 2008).
  
  
Entity Lung cancer
Prognosis Using proteomic technologies, ATP5B has been found to be associated with McAb4E7 antigen. In an immunohistochemical study, an abnormal expression has been shown in non-small cell lung cancer (NSCLC) with McAb4E7 antigen on the cell membrane of tumors but such expression has not been shown in small cell lung cancer (SCLC). Through this particular study, the abnormal expression of ATP5B protein on cell surface can be presented as a potential tumor associated antigen in immunodiagnostic and immunotherapy for NSCLC. ATP5B may be a potential marker and a therapeutic target for immunotherapy in NSCLC on cell surface (Lu et al., 2009).
  
  
Entity Hepatocellular cancer
Prognosis β-F1-ATPase is known to be a high-density lipoprotein (HDL) receptor for apolipoprotein A-I and is localized on the plasma membrane of rat and human hepatocytes and HepG2 cells (Martinez et al., 2003). The expression of ATP5B is controlled during post-transcriptional level of cell cycle and oncogenesis. MiR-127-5p 3'UTR of β-F1-ATPase which shows much expression in fetal liver targets mRNA (β-mRNA). ATP5B expression is reduced in many types of cancer, but miR-127-5p does not show expression in some cancers. miR-127-5p has an important role in regulating the activity of mitochondrial bioenergetics in cancers (Izquierdo and Cuezva, 1997). ATP5B expression in the liver has been shown to be controlled at the post-transcriptional level, and this control was found to be induced by miR-127-5p. miR-127-5p inhibits β-F1-ATPase mRNA translation in humans (Willers et al., 2012).
  
  
Entity Acute myeloid leukemia
Prognosis ATP5B gene expression and ATP synthase activity was found to be downregulated in patients with acute myeloid leukemia (AML). The decline in the activity of the ATP synthase and the downregulation of ATP5B shows a positive correlation to Adriamycin resistance in primary leukemia cells (Li et al., 2009). ATP5B has been shown to play an important role in multi-drug resistance mechanism in relapsed or refractory showing AML patients (Xiao et al., 2013). The upregulation of ATP5B was found to inhibit growth of adriamycin induced leukemia cells and was also found to decrease resistance for adriamycin triggered apoptosis (Xiao et al., 2013).
  
  
Entity Other disease
Note ATP5B gene has been also found to be associated with Alzheimer, Parkinson and Huntington disease. ATP5B and MDH1 were found to be involved in the energy metabolism, whose overexpression in null cell adenomas pave a new way of exploring the oncogenesis of these tumors (Hu et al., 2007).
  

Bibliography

Cancer abolishes the tissue type-specific differences in the phenotype of energetic metabolism.
Acebo P, Giner D, Calvo P, Blanco-Rivero A, Ortega AD, Fernandez PL, Roncador G, Fernandez-Malave E, Chamorro M, Cuezva JM.
Transl Oncol. 2009 Aug 18;2(3):138-45.
PMID 19701498
 
HIV-1 Vpr modulates macrophage metabolic pathways: a SILAC-based quantitative analysis.
Barrero CA, Datta PK, Sen S, Deshmane S, Amini S, Khalili K, Merali S.
PLoS One. 2013 Jul 12;8(7):e68376. doi: 10.1371/journal.pone.0068376. Print 2013.
PMID 23874603
 
Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase.
Chi SL, Wahl ML, Mowery YM, Shan S, Mukhopadhyay S, Hilderbrand SC, Kenan DJ, Lipes BD, Johnson CE, Marusich MF, Capaldi RA, Dewhirst MW, Pizzo SV.
Cancer Res. 2007 May 15;67(10):4716-24.
PMID 17510399
 
The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis.
Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, Hanash SM, Beer DG.
Carcinogenesis. 2004 Jul;25(7):1157-63. Epub 2004 Feb 12.
PMID 14963017
 
The bioenergetic signature of cancer: a marker of tumor progression.
Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC.
Cancer Res. 2002 Nov 15;62(22):6674-81.
PMID 12438266
 
The tumor suppressor function of mitochondria: translation into the clinics.
Cuezva JM, Ortega AD, Willers I, Sanchez-Cenizo L, Aldea M, Sanchez-Arago M.
Biochim Biophys Acta. 2009 Dec;1792(12):1145-58. doi: 10.1016/j.bbadis.2009.01.006. Epub 2009 Jan 23. (REVIEW)
PMID 19419707
 
Investigation of the association between ATP2B4 and ATP5B genes with colorectal cancer.
Geyik E, Igci YZ, Pala E, Suner A, Borazan E, Bozgeyik I, Bayraktar E, Bayraktar R, Ergun S, Cakmak EA, Gokalp A, Arslan A.
Gene. 2014 May 1;540(2):178-82. doi: 10.1016/j.gene.2014.02.050. Epub 2014 Feb 26.
PMID 24583174
 
Gene expression profiling in human null cell pituitary adenoma tissue.
Hu J, Song H, Wang X, Shen Y, Chen F, Liu Y, Li S, Wang Y, Shou X, Zhang Y, Hu R.
Pituitary. 2007;10(1):47-52.
PMID 17308960
 
Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B.
Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ, Juan HF.
J Proteome Res. 2008 Apr;7(4):1433-44. doi: 10.1021/pr700742h. Epub 2008 Feb 15.
PMID 18275135
 
Control of the translational efficiency of beta-F1-ATPase mRNA depends on the regulation of a protein that binds the 3' untranslated region of the mRNA.
Izquierdo JM, Cuezva JM.
Mol Cell Biol. 1997 Sep;17(9):5255-68.
PMID 9271403
 
Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance.
Li RJ, Zhang GS, Chen YH, Zhu JF, Lu QJ, Gong FJ, Kuang WY.
Ann Oncol. 2010 Jul;21(7):1506-14. doi: 10.1093/annonc/mdp569. Epub 2009 Dec 27.
PMID 20038517
 
Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study.
Lin PC, Lin JK, Yang SH, Wang HS, Li AF, Chang SC.
Int J Colorectal Dis. 2008 Dec;23(12):1223-32. doi: 10.1007/s00384-008-0539-4. Epub 2008 Sep 4.
PMID 18769884
 
The presence of HIV-1 Tat protein second exon delays fas protein-mediated apoptosis in CD4+ T lymphocytes: a potential mechanism for persistent viral production.
Lopez-Huertas MR, Mateos E, Sanchez Del Cojo M, Gomez-Esquer F, Diaz-Gil G, Rodriguez-Mora S, Lopez JA, Calvo E, Lopez-Campos G, Alcami J, Coiras M.
J Biol Chem. 2013 Mar 15;288(11):7626-44. doi: 10.1074/jbc.M112.408294. Epub 2013 Jan 30.
PMID 23364796
 
Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas.
Lopez-Rios F, Sanchez-Arago M, Garcia-Garcia E, Ortega AD, Berrendero JR, Pozo-Rodriguez F, Lopez-Encuentra A, Ballestin C, Cuezva JM.
Cancer Res. 2007 Oct 1;67(19):9013-7.
PMID 17909002
 
Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.
Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT.
BMC Cancer. 2009 Jan 14;9:16. doi: 10.1186/1471-2407-9-16.
PMID 19144153
 
Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis.
Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R.
Nature. 2003 Jan 2;421(6918):75-9.
PMID 12511957
 
The human ATP synthase beta subunit gene: sequence analysis, chromosome assignment, and differential expression.
Neckelmann N, Warner CK, Chung A, Kudoh J, Minoshima S, Fukuyama R, Maekawa M, Shimizu Y, Shimizu N, Liu JD, et al.
Genomics. 1989 Nov;5(4):829-43.
PMID 2687158
 
Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance.
Shin YK, Yoo BC, Chang HJ, Jeon E, Hong SH, Jung MS, Lim SJ, Park JG.
Cancer Res. 2005 Apr 15;65(8):3162-70.
PMID 15833846
 
miR-127-5p targets the 3'UTR of human beta-F1-ATPase mRNA and inhibits its translation.
Willers IM, Martinez-Reyes I, Martinez-Diez M, Cuezva JM.
Biochim Biophys Acta. 2012 May;1817(5):838-48. doi: 10.1016/j.bbabio.2012.03.005. Epub 2012 Mar 10.
PMID 22433606
 
Deregulation of mitochondrial ATPsyn-beta in acute myeloid leukemia cells and with increased drug resistance.
Xiao X, Yang J, Li R, Liu S, Xu Y, Zheng W, Yi Y, Luo Y, Gong F, Peng H, Pei M, Deng M, Zhang G.
PLoS One. 2013 Dec 31;8(12):e83610. doi: 10.1371/journal.pone.0083610. eCollection 2013.
PMID 24391795
 
Genome-scale RNAi screen for host factors required for HIV replication.
Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC, Stec E, Ferrer M, Strulovici B, Hazuda DJ, Espeseth AS.
Cell Host Microbe. 2008 Nov 13;4(5):495-504. doi: 10.1016/j.chom.2008.10.004. Epub 2008 Oct 30.
PMID 18976975
 
Essentials for ATP synthesis by F1F0 ATP synthases.
von Ballmoos C, Wiedenmann A, Dimroth P.
Annu Rev Biochem. 2009;78:649-72. doi: 10.1146/annurev.biochem.78.081307.104803. (REVIEW)
PMID 19489730
 

Citation

This paper should be referenced as such :
Bozgeyik E, Arman K, Igci YZ
ATP5B (ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Genes/ATP5BID51209ch12q13.html


External links

Nomenclature
HGNC (Hugo)ATP5B   830
Cards
AtlasATP5BID51209ch12q13
Entrez_Gene (NCBI)ATP5B  506  ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide
AliasesATPMB; ATPSB; HEL-S-271
GeneCards (Weizmann)ATP5B
Ensembl hg19 (Hinxton)ENSG00000110955 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000110955 [Gene_View]  chr12:56638175-56646068 [Contig_View]  ATP5B [Vega]
ICGC DataPortalENSG00000110955
TCGA cBioPortalATP5B
AceView (NCBI)ATP5B
Genatlas (Paris)ATP5B
WikiGenes506
SOURCE (Princeton)ATP5B
Genetics Home Reference (NIH)ATP5B
Genomic and cartography
GoldenPath hg38 (UCSC)ATP5B  -     chr12:56638175-56646068 -  12q13.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)ATP5B  -     12q13.3   [Description]    (hg19-Feb_2009)
EnsemblATP5B - 12q13.3 [CytoView hg19]  ATP5B - 12q13.3 [CytoView hg38]
Mapping of homologs : NCBIATP5B [Mapview hg19]  ATP5B [Mapview hg38]
OMIM102910   
Gene and transcription
Genbank (Entrez)AK291085 BC016512 BI561028 DQ403107 DQ891585
RefSeq transcript (Entrez)NM_001686
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)ATP5B
Cluster EST : UnigeneHs.406510 [ NCBI ]
CGAP (NCI)Hs.406510
Alternative Splicing GalleryENSG00000110955
Gene ExpressionATP5B [ NCBI-GEO ]   ATP5B [ EBI - ARRAY_EXPRESS ]   ATP5B [ SEEK ]   ATP5B [ MEM ]
Gene Expression Viewer (FireBrowse)ATP5B [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevisibleExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)506
GTEX Portal (Tissue expression)ATP5B
Protein : pattern, domain, 3D structure
UniProt/SwissProtP06576   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtP06576  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProP06576
Splice isoforms : SwissVarP06576
Catalytic activity : Enzyme3.6.3.14 [ Enzyme-Expasy ]   3.6.3.143.6.3.14 [ IntEnz-EBI ]   3.6.3.14 [ BRENDA ]   3.6.3.14 [ KEGG ]   
PhosPhoSitePlusP06576
Domaine pattern : Prosite (Expaxy)ATPASE_ALPHA_BETA (PS00152)   
Domains : Interpro (EBI)AAA+_ATPase    ATP_synth_F1_bsu    ATPase_a/bsu_AS    ATPase_F1/V1/A1_a/bsu_N    ATPase_F1/V1/A1_a/bsu_nucl-bd    ATPase_F1/V1_bsu_C    P-loop_NTPase   
Domain families : Pfam (Sanger)ATP-synt_ab (PF00006)    ATP-synt_ab_N (PF02874)   
Domain families : Pfam (NCBI)pfam00006    pfam02874   
Domain families : Smart (EMBL)AAA (SM00382)  
Conserved Domain (NCBI)ATP5B
DMDM Disease mutations506
Blocks (Seattle)ATP5B
SuperfamilyP06576
Human Protein AtlasENSG00000110955
Peptide AtlasP06576
HPRD00044
IPIIPI00303476   IPI01021250   IPI01022109   IPI01021986   IPI01021839   IPI01021699   IPI01022836   
Protein Interaction databases
DIP (DOE-UCLA)P06576
IntAct (EBI)P06576
FunCoupENSG00000110955
BioGRIDATP5B
STRING (EMBL)ATP5B
ZODIACATP5B
Ontologies - Pathways
QuickGOP06576
Ontology : AmiGOangiogenesis  osteoblast differentiation  transporter activity  protein binding  ATP binding  nucleus  mitochondrion  mitochondrial proton-transporting ATP synthase complex  mitochondrial proton-transporting ATP synthase, catalytic core  mitochondrial matrix  mitochondrial matrix  plasma membrane  generation of precursor metabolites and energy  lipid metabolic process  ATP biosynthetic process  ATP biosynthetic process  negative regulation of cell adhesion involved in substrate-bound cell migration  mitochondrion organization  cell surface  proton transport  membrane  ATPase activity  transmembrane transporter activity  extracellular matrix  mitochondrial membrane  MHC class I protein binding  mitochondrial nucleoid  mitochondrial ATP synthesis coupled proton transport  mitochondrial ATP synthesis coupled proton transport  myelin sheath  angiostatin binding  positive regulation of blood vessel endothelial cell migration  proton-transporting ATP synthase complex  proton-transporting ATP synthase activity, rotational mechanism  proton-transporting ATPase activity, rotational mechanism  regulation of intracellular pH  extracellular exosome  ATP hydrolysis coupled cation transmembrane transport  
Ontology : EGO-EBIangiogenesis  osteoblast differentiation  transporter activity  protein binding  ATP binding  nucleus  mitochondrion  mitochondrial proton-transporting ATP synthase complex  mitochondrial proton-transporting ATP synthase, catalytic core  mitochondrial matrix  mitochondrial matrix  plasma membrane  generation of precursor metabolites and energy  lipid metabolic process  ATP biosynthetic process  ATP biosynthetic process  negative regulation of cell adhesion involved in substrate-bound cell migration  mitochondrion organization  cell surface  proton transport  membrane  ATPase activity  transmembrane transporter activity  extracellular matrix  mitochondrial membrane  MHC class I protein binding  mitochondrial nucleoid  mitochondrial ATP synthesis coupled proton transport  mitochondrial ATP synthesis coupled proton transport  myelin sheath  angiostatin binding  positive regulation of blood vessel endothelial cell migration  proton-transporting ATP synthase complex  proton-transporting ATP synthase activity, rotational mechanism  proton-transporting ATPase activity, rotational mechanism  regulation of intracellular pH  extracellular exosome  ATP hydrolysis coupled cation transmembrane transport  
Pathways : KEGGOxidative phosphorylation    Alzheimer's disease    Parkinson's disease    Huntington's disease   
REACTOMEP06576 [protein]
REACTOME PathwaysR-HSA-2151201 [pathway]   
NDEx NetworkATP5B
Atlas of Cancer Signalling NetworkATP5B
Wikipedia pathwaysATP5B
Orthology - Evolution
OrthoDB506
GeneTree (enSembl)ENSG00000110955
Phylogenetic Trees/Animal Genes : TreeFamATP5B
HOVERGENP06576
HOGENOMP06576
Homologs : HomoloGeneATP5B
Homology/Alignments : Family Browser (UCSC)ATP5B
Gene fusions - Rearrangements
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerATP5B [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)ATP5B
dbVarATP5B
ClinVarATP5B
1000_GenomesATP5B 
Exome Variant ServerATP5B
ExAC (Exome Aggregation Consortium)ATP5B (select the gene name)
Genetic variants : HAPMAP506
Genomic Variants (DGV)ATP5B [DGVbeta]
DECIPHERATP5B [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisATP5B 
Mutations
ICGC Data PortalATP5B 
TCGA Data PortalATP5B 
Broad Tumor PortalATP5B
OASIS PortalATP5B [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICATP5B  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDATP5B
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
LOVD (Leiden Open Variation Database)MSeqDR-LSDB Mitochondrial Disease Locus Specific Database
BioMutasearch ATP5B
DgiDB (Drug Gene Interaction Database)ATP5B
DoCM (Curated mutations)ATP5B (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)ATP5B (select a term)
intoGenATP5B
NCG5 (London)ATP5B
Cancer3DATP5B(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM102910   
Orphanet
MedgenATP5B
Genetic Testing Registry ATP5B
NextProtP06576 [Medical]
TSGene506
GENETestsATP5B
Target ValidationATP5B
Huge Navigator ATP5B [HugePedia]
snp3D : Map Gene to Disease506
BioCentury BCIQATP5B
ClinGenATP5B
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD506
Chemical/Pharm GKB GenePA25122
Clinical trialATP5B
Miscellaneous
canSAR (ICR)ATP5B (select the gene name)
Probes
Litterature
PubMed134 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineATP5B
EVEXATP5B
GoPubMedATP5B
iHOPATP5B
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 16:57:28 CEST 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.